We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

188 hedge funds and large institutions have $411M invested in Revance Therapeutics, Inc. in 2024 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 60 increasing their positions, 54 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more call options, than puts

Call options by funds: $4.96M | Put options by funds: $2.92M

11% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 54

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

7% less first-time investments, than exits

New positions opened: 38 | Existing positions closed: 41

3% less funds holding

Funds holding: 193 → 188 (-5)

36% less capital invested

Capital invested by funds: $644M → $411M (-$233M)

Holders
188
Holders Change
-5
Holders Change %
-2.59%
% of All Funds
2.71%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
38
Increased
60
Reduced
54
Closed
41
Calls
$4.96M
Puts
$2.92M
Net Calls
+$2.04M
Net Calls Change
-$10.7M

Top Buyers

Rank Fund Capital Flow
1
Barclays
Barclays
United Kingdom
+$15.8M
2
Capital World Investors
Capital World Investors
California
+$11.9M
3
SCM
Stonepine Capital Management
Oregon
+$11.7M
4
SCM
Suvretta Capital Management
New York
+$9.47M
5
Franklin Resources
Franklin Resources
California
+$9.08M

Top Sellers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
-$9.18M
2
Jennison Associates
Jennison Associates
New York
-$9.07M
3
JP Morgan Chase
JP Morgan Chase
New York
-$8.82M
4
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$4.43M
5
IHAM
Integral Health Asset Management
New York
-$3.96M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$2.67M -$1.42M -240,179 -31%
Bank of America
27
Bank of America
North Carolina
$2.48M +$1.75M +296,003 +142%
EAM
28
EULAV Asset Management
Florida
$2.46M -$770K -130,000 -21%
SCM
29
Sio Capital Management
New York
$2.31M +$2.78M +468,871 New
EWM
30
Essex Woodlands Management
Texas
$2.25M – – –
GTC
31
Ghost Tree Capital
New York
$2.21M +$444K +75,000 +20%
HighTower Advisors
32
HighTower Advisors
Illinois
$2.19M +$231K +38,966 +10%
Renaissance Technologies
33
Renaissance Technologies
New York
$1.84M +$2.21M +373,700 New
N
34
Nuveen
North Carolina
$1.73M -$1.07M -181,154 -34%
William Blair & Company
35
William Blair & Company
Illinois
$1.62M +$215K +36,318 +12%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$1.5M -$181K -30,621 -9%
D.E. Shaw & Co
37
D.E. Shaw & Co
New York
$1.47M -$673K -113,640 -28%
Schroder Investment Management Group
38
Schroder Investment Management Group
United Kingdom
$1.42M – – –
DA
39
DCF Advisers
Connecticut
$1.3M +$38.5K +6,500 +3%
Two Sigma Investments
40
Two Sigma Investments
New York
$1.27M +$1.52M +257,397 New
UOC
41
UBS O'Connor
Illinois
$1.25M +$858K +145,000 +132%
MCM
42
Moore Capital Management
New York
$1.23M +$592K +100,000 +67%
CM
43
CM Management
Florida
$1.23M +$1.04M +175,000 +233%
AA
44
AlphaCentric Advisors
Puerto Rico
$1.21M +$148K +25,000 +11%
Mirae Asset Global Investments
45
Mirae Asset Global Investments
South Korea
$1.11M -$2.4K -405 -1%
EIM
46
Essex Investment Management
Massachusetts
$1.08M +$579K +97,741 +80%
BNP Paribas Financial Markets
47
BNP Paribas Financial Markets
France
$1.04M +$970K +163,809 +342%
TCM
48
Tang Capital Management
California
$984K +$1.18M +200,000 New
Assenagon Asset Management
49
Assenagon Asset Management
Luxembourg
$978K – – –
Swiss National Bank
50
Swiss National Bank
Switzerland
$958K +$178K +30,000 +18%
1
2
3 4 5

RVNC Hedge Fund Activity: Q1 2024 in Review

188 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q1 2024, worth a combined $411M — down 36% from $644M a quarter earlier.

Sellers outnumbered buyers: 41 funds closed out of RVNC and 38 opened new positions — a net loss of 3 holders — while 54 trimmed existing stakes and 60 added.

The largest buyer was Barclays, adding an estimated $15.8M. The largest seller was Invesco, cutting an estimated $9.18M.

  • 188 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q1 2024, down from 193 in Q4 2023.
  • Funds reported $411M of Revance Therapeutics, Inc. stock for Q1 2024, down 36% quarter-over-quarter.
  • 38 funds opened new Revance Therapeutics, Inc. positions in Q1 2024 and 41 closed out, a net change of -3 holders.
  • The largest Revance Therapeutics, Inc. buyer in Q1 2024 was Barclays, an estimated $15.8M added.
  • The largest Revance Therapeutics, Inc. seller in Q1 2024 was Invesco, an estimated $9.18M sold.

Based on aggregated 13F filings for Q1 2024.